Address
3115 Merryfield Row
San Diego, CA 92121
United States of America (the)
Phone
858 465 6511
Website
Sector
Healthcare
Industry
Biotechnology
Employees
103
First IPO Date
July 16, 2021
| Name | Title | Pay | Year Born |
| Jonathan E. Lim | Co-Founder, Chairman & Chief Executive Officer | 1.16M | 1972 |
| Michael D. Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director | 93,181 | 1958 |
| Ebun S. Garner | Chief Legal Officer & Corporate Secretary | 607,440 | 1972 |
| Shannon Morris | Chief Medical Officer | 772,700 | 1970 |
| David Chacko | Chief Financial Officer & Chief Business Officer | 775,216 | 1984 |
| Chandra D. Lovejoy | Chief Regulatory Affairs Officer | 0 | 1971 |
| Lisa Tesvich-Bonora | Chief People Officer | 0 | N/A |
| Minli Xie | Senior Vice President of Pharmaceutical Development & Operations | 0 | N/A |
| Brian L. Baker | Senior Vice President of Finance | 0 | 1967 |
| Robert Shoemaker | Chief Scientific Officer | 0 | 1981 |
| Alison Tjosvold Milhous | Senior Vice President of Accounting | 0 | 1979 |
| Nik Chetwyn | Chief Operating Officer | 0 | N/A |
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.